BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer
BriaCell has received agreement and positive feedback from its End of Phase II meeting with the FDA for lead clinical...
Cancer
ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas
Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary...
Hinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical Development
Barry Selick, Ph.D., successful biopharmaceutical scientist, senior executive and entrepreneur, appointed Chief Executive Officer Carin Rollins, Hinge Bio co-founder, becomes...
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma
Figure Initial treatment imaging from first patient treated in the ReSPECT-GBM Phase 2b trialAUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE)...
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
WILMETTE, Ill., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing...
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
Patient Access Initiative Addresses €1 Billion Annual Market in GermanyBERKELEY, US and MAINZ, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) --...
BioSenic appoints Dr Carole Nicco as Chief Scientific Officer
Dr Nicco will oversee the development of pipeline across BioSenic’s cell therapy and autoimmune disease platform and will be responsible...
Junshi Biosciences Announces Acceptance of NDA for VV116 in China
SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study
SHANGHAI, China, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
Burning Rock provides an update on 2022 revenue guidance
GUANGZHOU, China, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or...
Shineco Entered Into Framework Agreement Relating to Acquisition of Antiviral Fabric Producer Chongqing Wintus Group
BEIJING, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of...
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
Research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of...
Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
WALTHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors
CINCINNATI, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a...
CorMedix Inc. Announces Promotions in Commercial and Tech Ops
BERKELEY HEIGHTS, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
WORCESTER, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical...
Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma
-Initiation of Phase 2b trial follows clearance from the US Food and Drug Administration (FDA) and Spanish Agency for Medicines...
Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors
BMF-219 is the first menin inhibitor to be clinically studied in patients with KRAS-mutated non-small cell lung cancer (NSCLC), colorectal...
Oncotelic Announces the launch of PDAO token
- PDAO is to Revolutionize Decentralized Autonomous Organization (DAO) AGOURA HILLS, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics,...
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using...